<code id='0E2B800B3F'></code><style id='0E2B800B3F'></style>
    • <acronym id='0E2B800B3F'></acronym>
      <center id='0E2B800B3F'><center id='0E2B800B3F'><tfoot id='0E2B800B3F'></tfoot></center><abbr id='0E2B800B3F'><dir id='0E2B800B3F'><tfoot id='0E2B800B3F'></tfoot><noframes id='0E2B800B3F'>

    • <optgroup id='0E2B800B3F'><strike id='0E2B800B3F'><sup id='0E2B800B3F'></sup></strike><code id='0E2B800B3F'></code></optgroup>
        1. <b id='0E2B800B3F'><label id='0E2B800B3F'><select id='0E2B800B3F'><dt id='0E2B800B3F'><span id='0E2B800B3F'></span></dt></select></label></b><u id='0E2B800B3F'></u>
          <i id='0E2B800B3F'><strike id='0E2B800B3F'><tt id='0E2B800B3F'><pre id='0E2B800B3F'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          Wikipedia

          author:leisure time    - browse:83586
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP

          A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

          Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

          advertisement

          Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time